

Formulary Updates for Standard Control with Advanced Control Specialty Formulary® effective July 1, 2026

Products to be **added** to the formulary:

Formulary Additions

Drug Class	Product(s) Added
Central Nervous System, Antipsychotics	INVEGA HAFYERA^, INVEGA TRINZA^
Central Nervous System, Multiple Sclerosis	BRIUMVI^, TYRUKO^
Central Nervous System, Myasthenia Gravis	EPYSQLI^
Endocrine And Metabolic, Androgens	XYOSTED (Non-Preferred)
Gastrointestinal, Miscellaneous	REBYOTA^ (Non-Preferred)

These products will move **from non-preferred to preferred**:

Tier Changes: Non-Preferred to Preferred

Drug Class	Product Name(s)
Central Nervous System, Antidepressants	SPRAVATO
Central Nervous System, Antipsychotics	INVEGA SUSTENNA

Products that will be **removed** from the formulary:

Formulary Removals

Drug Class	Removed Product(s)	Formulary Options
Autoimmune Agents, Self-Administered	PYZCHIVA SC (by Sandoz), STELARA SC	<u>Crohn's Disease</u> : ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ENTYVIO SC, HYRIMOZ (by Cordavis), PYZCHIVA SC (by Cordavis), RINVOQ, SKYRIZI SC, TREMFYA SC, YESINTEK SC <u>Psoriasis</u> : ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, BIMZELX, HYRIMOZ (by Cordavis), OTEZLA, OTEZLA XR, PYZCHIVA SC (by Cordavis), SKYRIZI SC, SOTYKTU, TREMFYA SC, YESINTEK SC <u>Psoriatic Arthritis</u> : ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, COSENTYX SC, ENBREL, HYRIMOZ (by Cordavis), OTEZLA, OTEZLA XR, PYZCHIVA SC (by Cordavis), RINVOQ, SKYRIZI SC, TREMFYA SC, YESINTEK SC <u>Ulcerative Colitis</u> : ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ENTYVIO SC,

Drug Class	Removed Product(s)	Formulary Options
		HYRIMOZ (by Cordavis), PYZCHIVA SC (by Cordavis), RINVOQ, SKYRIZI SC, TREMFYA SC, VELSIPITY, YESINTEK SC, ZEPOSIA
Central Nervous System, Multiple Sclerosis	TYSABRI	<i>dimethyl fumarate delayed-rel, fingolimod, glatiramer, teriflunomide, AVONEX, BAFIERTAM, BETASERON, BRIUMVI, KESIMPTA, MAYZENT, OCREVUS, REBIF, TYRUKO, VUMERITY, ZEPOSIA</i>
Hematologic, Paroxysmal Nocturnal Hemoglobinuria (PNH) Agents	SOLIRIS**	EMPAVELI, EPYSQLI
Respiratory, Anticholinergic/ Beta Agonist Combinations	COMBIVENT RESPIMAT	<i>ipratropium-albuterol inhalation solution, ANORO ELLIPTA, STIOLTO RESPIMAT</i>
Topical/Dermatology, Acne	TWYNEO	<i>adapalene (except adapalene pad), benzoyl peroxide, clindamycin gel (except NDC 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, dapsone, erythromycin solution, erythromycin-benzoyl peroxide, tazarotene, tretinoin, AKLIEF, EPIDUO, WINLEVI</i>
Topical/Dermatology, Antifungals	ECOZA	<i>ciclopirox, clotrimazole, econazole, ketoconazole cream 2%, naftifine</i>
Topical/Dermatology, Local Anesthetics	ZTLIDO	<i>lidocaine patch</i>

These products will move **from preferred to non-preferred:**

Tier Changes: Preferred to Non-Preferred

Drug Class	Product Name(s)	Formulary Options
Autoimmune Agents, Self-Administered	ORENCIA 50MG/0.4ML, ORENCIA 87.5MG/0.7ML, XELJANZ SOLUTION 1MG/1ML	ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ENBREL, HYRIMOZ (by Cordavis)
Central Nervous System, Antipsychotics	PERSERIS	ABILIFY ASIMTUFII, ABILIFY MAINTENA, INVEGA HAFYERA, INVEGA SUSTENNA, INVEGA TRINZA

UPPERCASE represents brand products
lowercase represents generic products
****SOLIRIS** currently excluded for Myasthenia Gravis

^Previously New to Market Block
*****Multi-source Brand Product

This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates. Information listed is current as of April 1, 2026 and subject to change.